In Embase, the following terms were used: ('sodium glucose cotransporter 2 inhibitor' OR 'SGLT2 inhibitor' OR empagliflozin OR dapagliflozin OR canagliflozin) AND ('heart failure with preserved ejection fraction' OR HFpEF OR 'diastolic heart failure') AND ('placebo' OR 'standard care' OR 'usual care'). This evidence concerns the gene SLC5A2 and heart failure.